FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772007188> ?p ?o ?g. }

• W2772007188 endingPage "e145" @default.
• W2772007188 startingPage "e139" @default.
• W2772007188 abstract "Background In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of 5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of apixaban drug levels, as determined by apixaban-calibrated anti-factor Xa (anti-Xa) activity, has previously been measured in small cohorts; however, the association between anti-Xa activity and clinical outcomes and the predictors of variability in anti-Xa activity have not been well studied in the AF population. Methods and Results Anti-Xa activity was measured before taking the morning dose, 3 months after enrollment in the AVERROES study using a calibrated anti-Xa assay (Rotachrom). Patients with two of the following criteria—age >80; weight <60 kg; or creatinine >133 μg/L—received 2.5 mg twice daily (n = 145), while all others received 5 mg twice daily (n = 2,247). A total of 2,392 patients were included, with median follow-up of 1.1 years. Median apixaban anti-Xa activity was 122 ng/mL (interquartile range [IQR]: 63–198 ng/mL) for the entire group; 99 ng/mL (IQR: 60–146 ng/mL) for the 2.5-mg group; and 125 ng/mL (IQR: 64–202 ng/mL) for the 5-mg group (p = 0.003). A relationship was evident between bleeding and anti-Xa activity (p = 0.01), which was driven by minor bleeding. No relationship was evident between major bleeding or stroke/systemic embolism and anti-Xa activity. In those receiving the 5-mg dose, estimated glomerular filtration rate, sex, and age had the strongest association with anti-Xa activity. Conclusion There is considerable variability in anti-Xa activity among AF patients receiving apixaban. Rates of major bleeding and stroke/systemic embolism were low irrespective of anti-Xa activity. Clinical Trial Registration ClinicalTrials.gov NCT00496769; https://clinicaltrials.gov/ct2/show/NCT00496769." @default.
• W2772007188 created "2017-12-22" @default.
• W2772007188 creator A5000914852 @default.
• W2772007188 creator A5002452498 @default.
• W2772007188 creator A5018419311 @default.
• W2772007188 creator A5025928709 @default.
• W2772007188 creator A5039531642 @default.
• W2772007188 creator A5055606506 @default.
• W2772007188 creator A5055785288 @default.
• W2772007188 creator A5061132830 @default.
• W2772007188 creator A5079046512 @default.
• W2772007188 creator A5087630518 @default.
• W2772007188 date "2017-07-01" @default.
• W2772007188 modified "2023-10-16" @default.
• W2772007188 title "Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial" @default.
• W2772007188 cites W1517835164 @default.
• W2772007188 cites W1547546593 @default.
• W2772007188 cites W1964424199 @default.
• W2772007188 cites W2018856451 @default.
• W2772007188 cites W2062786076 @default.
• W2772007188 cites W2103196751 @default.
• W2772007188 cites W2108745446 @default.
• W2772007188 cites W2116559262 @default.
• W2772007188 cites W2149388786 @default.
• W2772007188 cites W2155965977 @default.
• W2772007188 cites W2162508946 @default.
• W2772007188 cites W2167698566 @default.
• W2772007188 cites W2175458832 @default.
• W2772007188 cites W2194419520 @default.
• W2772007188 cites W2205543890 @default.
• W2772007188 cites W2566947560 @default.
• W2772007188 cites W2607031541 @default.
• W2772007188 cites W2989714602 @default.
• W2772007188 doi "https://doi.org/10.1055/s-0037-1613679" @default.
• W2772007188 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6524853" @default.
• W2772007188 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31249919" @default.
• W2772007188 hasPublicationYear "2017" @default.
• W2772007188 type Work @default.
• W2772007188 sameAs 2772007188 @default.
• W2772007188 citedByCount "27" @default.
• W2772007188 countsByYear W27720071882018 @default.
• W2772007188 countsByYear W27720071882019 @default.
• W2772007188 countsByYear W27720071882020 @default.
• W2772007188 countsByYear W27720071882021 @default.
• W2772007188 countsByYear W27720071882022 @default.
• W2772007188 countsByYear W27720071882023 @default.
• W2772007188 crossrefType "journal-article" @default.
• W2772007188 hasAuthorship W2772007188A5000914852 @default.
• W2772007188 hasAuthorship W2772007188A5002452498 @default.
• W2772007188 hasAuthorship W2772007188A5018419311 @default.
• W2772007188 hasAuthorship W2772007188A5025928709 @default.
• W2772007188 hasAuthorship W2772007188A5039531642 @default.
• W2772007188 hasAuthorship W2772007188A5055606506 @default.
• W2772007188 hasAuthorship W2772007188A5055785288 @default.
• W2772007188 hasAuthorship W2772007188A5061132830 @default.
• W2772007188 hasAuthorship W2772007188A5079046512 @default.
• W2772007188 hasAuthorship W2772007188A5087630518 @default.
• W2772007188 hasBestOaLocation W27720071881 @default.
• W2772007188 hasConcept C119060515 @default.
• W2772007188 hasConcept C126322002 @default.
• W2772007188 hasConcept C127413603 @default.
• W2772007188 hasConcept C19720800 @default.
• W2772007188 hasConcept C2776301958 @default.
• W2772007188 hasConcept C2778661090 @default.
• W2772007188 hasConcept C2779161974 @default.
• W2772007188 hasConcept C2780306776 @default.
• W2772007188 hasConcept C2780638905 @default.
• W2772007188 hasConcept C2780645631 @default.
• W2772007188 hasConcept C42219234 @default.
• W2772007188 hasConcept C71924100 @default.
• W2772007188 hasConcept C78519656 @default.
• W2772007188 hasConcept C90924648 @default.
• W2772007188 hasConceptScore W2772007188C119060515 @default.
• W2772007188 hasConceptScore W2772007188C126322002 @default.
• W2772007188 hasConceptScore W2772007188C127413603 @default.
• W2772007188 hasConceptScore W2772007188C19720800 @default.
• W2772007188 hasConceptScore W2772007188C2776301958 @default.
• W2772007188 hasConceptScore W2772007188C2778661090 @default.
• W2772007188 hasConceptScore W2772007188C2779161974 @default.
• W2772007188 hasConceptScore W2772007188C2780306776 @default.
• W2772007188 hasConceptScore W2772007188C2780638905 @default.
• W2772007188 hasConceptScore W2772007188C2780645631 @default.
• W2772007188 hasConceptScore W2772007188C42219234 @default.
• W2772007188 hasConceptScore W2772007188C71924100 @default.
• W2772007188 hasConceptScore W2772007188C78519656 @default.
• W2772007188 hasConceptScore W2772007188C90924648 @default.
• W2772007188 hasIssue "02" @default.
• W2772007188 hasLocation W27720071881 @default.
• W2772007188 hasLocation W27720071882 @default.
• W2772007188 hasLocation W27720071883 @default.
• W2772007188 hasLocation W27720071884 @default.
• W2772007188 hasOpenAccess W2772007188 @default.
• W2772007188 hasPrimaryLocation W27720071881 @default.
• W2772007188 hasRelatedWork W1993190469 @default.
• W2772007188 hasRelatedWork W1993758186 @default.
• W2772007188 hasRelatedWork W2049310472 @default.
• W2772007188 hasRelatedWork W2321904733 @default.
• W2772007188 hasRelatedWork W2597099584 @default.

• next